Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Germany-based caprotec bioanalytics opens US Subsidiary in Massachusetts; appoints president


Burlington, MA, and Berlin, Germany, November 19, 2009 – caprotec bioanalytics GmbH announced today the opening of its US subsidiary based in Burlington, MA. caprotec Inc. will be responsible for North American sales, marketing and support of caprotec’s proprietary Capture Compound Mass Spectrometry (CCMS) technology and its related products.

caprotec is partnering with Genovative Solutions, LLC in the area of sales and marketing. Genovative’s founder Jeff Protentis is acting as caprotec’s lead agent for North America to intensify promotion and sales of caprotec’s products and services.

The company also announced the appointment of Dr. Christian Jurinke as President of its US subsidiary caprotec Inc. Dr Jurinke, a 12 year veteran of developing and commercializing products for life science ventures, joined caprotec in 2008 to head the company’s key product commercialization and help manage the company’s growing distribution channels. Before joining caprotec Dr. Jurinke most recently served in a number of senior management positions at Sequenom, Inc. in San Diego.

“The opening of our US subsidiary is an important milestone in commercializing our CCMS technology,” stated Dr. Hubert Köster, CEO of caprotec bioanalytics. “We have well-established distribution channels in Europe and Japan. The steadily increasing demand for our products in North America necessitated a US presence as the most effective and efficient strategy.”

“Our US subsidiary is now fully operational to serve the North American proteomics research community with our growing family of products,” said Dr. Jurinke. “Through our US subsidiary we can now rapidly execute the increasing amount of orders, and we are able to expand our operations as demand is increasing.”

The company’s caproKits address the needs of the proteomics community as a novel and direct way to investigate interactions of small molecules with proteins and are used to identify protein kinases, cAMP- and cGMP-binding proteins, methyl transferases or metallo-proteases directly from biological samples. Additional caproKits for multiple new applications are currently under development. In collaborations with pharmaceutical and biotech companies, caprotec uses its proprietary Capture Compound Mass Spectrometry (CCMS) technology to determine protein profiles of drug interactions to identify drug targets as well as side effect causing off-target proteins or to elucidate the mode of action.

About caprotec bioanalytics GmbH
caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds™. They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry or gel electrophoresis and Western blotting. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.

About Genovative Solutions, LLC
Genovative Solutions is a consulting company specializing in the commercialization of products and technologies for the scientific products industry. Genovative helps companies design, develop and implement strategies and tactics to ensure commercial success of technologies, products and services in the fields of Proteomics, Genomics, Genetics and Analytical tools. Clients served are early stage companies pursuing commercial success and non-US based companies seeking to penetrate the North American market.

For further information please contact:
caprotec bioanalytics GmbH
Corporate Communications
Phone: +49 (0)30-6392-3990
www.caprotec.com

or
Dr. Christian Jurinke, President
caprotec Inc.
Phone: + 1 (781) 685-4992
info@caprotec.com

or
Jeff Protentis, Founder and President
Genovative Solutions
jprotentis@genovative-solutions.com
www.genovative-solutions.com


Publisher Contact Information:

caprotec bioanalytics
+ 1 (781) 685-4992
info@caprotec.com

Company profile of caprotec bioanalytics
Past press releases of caprotec bioanalytics.

Data


27,619
Tech investments
From our Online Data Service
17,820
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 4€3.3MNanotechnology
Dec 3€21.0MBusiness applications
Dec 2€7.0MDigital signal processing
Dec 2€7.4MBiotechnology
Nov 30€3.7MConsumer electronics
Nov 12€20.0MAgriculture related
Jan 17€13.0MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.